S1RA

Research use only, not for human use.

A potent and selective sigma-1 receptor antagonist with Ki of 17 nM; shows excellent selectivity over sigma-2 receptor (Ki>1 uM).

A potent and selective sigma-1 receptor antagonist with Ki of 17 nM; shows excellent selectivity over sigma-2 receptor (Ki>1 uM); shows high activity in the mouse capsaicin model of neurogenic pain, exerts dose-dependent antinociceptive effects in several neuropathic pain models.Pain Phase 2 Clinical.

——

Animal Model:WT and TRPA1 KO mice with AITC (10 μl at 10 mM) in their hind paws Dosage:40 mg/kg Administration:IP; single dose; 24-h before evaluation Result:Produced a substantial reduction in pain-related responses to intradermal AITC in WT mice.

E-52862

Autophagy

Sigma receptor

σ1

Neurological Disease

Pain

878141-96-9

337.4155

C20H23N3O2

>98% (HPLC)

10 mM in DMSO

CC1=CC(OCCN2CCOCC2)=NN1C1=CC2=CC=CC=C2C=C1

Morpholine, 4-[2-[[5-methyl-1-(2-naphthalenyl)-1H-pyrazol-3-yl]oxy]ethyl]-

(-20℃)

With Ice Pack

≥ 2 years